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ABSTRACT
Proliferator-activated receptor γ (PPARγ) activation can result in transcription 
of proteins involved in oxidative stress defence and mitochondrial biogenesis which 
could rescue mitochondrial dysfunction in Parkinson’s disease (PD).The PPARγ agonist 
pioglitazone is protective in models of PD; however side effects have limited its clinical 
use. The cannabinoid Δ9-tetrahydrocannabinol (Δ9-THC) may have PPARγ dependent 
anti-oxidant properties. Here we investigate the effects of Δ9-THC and pioglitazone on 
mitochondrial biogenesis and oxidative stress. Differentiated SH-SY5Y neuroblastoma 
cells were exposed to the PD relevant mitochondrial complex 1 inhibitor 1-methyl-
4-phenylpyridinium iodide (MPP+). We found that only Δ9-THC was able to restore 
mitochondrial content in MPP+ treated SH-SY5Y cells in a PPARγ dependent manner 
by increasing expression of the PPARγ co-activator 1α (PGC-1α), the mitochondrial 
transcription factor (TFAM) as well as mitochondrial DNA content. Co-application of Δ9-
THC with pioglitazone further increased the neuroprotection against MPP+ toxicity as 
compared to pioglitazone treatment alone. Furthermore, using lentiviral knock down 
of the PPARγ receptor we showed that, unlike pioglitazone, Δ9-THC resulted in a PPARγ 
dependent reduction of MPP+ induced oxidative stress. We therefore suggest that, 
in contrast to pioglitazone, Δ9-THC mediates neuroprotection via PPARγ-dependent 
restoration of mitochondrial content which may be beneficial for PD treatment.
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative 
disorder in which the progressive loss of dopaminergic 
neurons within the substantia nigra pars compacta leads to 
neurochemical imbalance in the basal ganglia resulting in 
motor dysfunction. Although PD can initially be managed 
through dopamine replacement therapy, there are currently 
no treatment strategies available to halt the progression of the 
disease. Activation of the peroxisome proliferator activated 
receptor gamma (PPARγ) by the specific thiazolidinedione 
(TZD) agonists rosiglitazone and pioglitazone has been found 
protective in both animal and cell culture models of PD [1-
6]. Furthermore, the presence of neuronal PPARγ receptors 
has recently been reported in the substantia nigra pars 
compacta of non-human primates [7]. The PPARγ receptor is 
a ligand activated nuclear receptor that initiates transcription 
of genes containing a PPAR response element (PPRE) 
in their promoter region [8]. So far, the neuroprotective 
properties of PPARγ agonists in PD have been attributed 
to an induction of anti-inflammatory responses [3, 5, 9] 
and induction of genes involved in oxidative stress defence 
such as superoxide dismutase 1 (SOD1) and catalase [2]. 
However, activation of the PPARγ receptor can also regulate 
the de novo synthesis of mitochondria [10, 11] by inducing the 
expression of PPARγ coactivator-1α (PGC-1α) as well as the 
mitochondrial transcription factor A (TFAM), both of which 
are key regulators of mitochondrial biogenesis [11, 12]. This 
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is particularly interesting as a meta-analysis of 9 genome wide 
expression studies demonstrated that gene sets controlled by 
PGC-1α were down-regulated in PD patients [13]. Restoration 
of PGC-1α levels has been shown to protect against complex 
1 inhibition as well as in genetic models of PD such as A53T 
mutation of α-synuclein [13-15] and Park2 mutations [16]. 
Furthermore, the TZD rosiglitazone can restore mitochondrial 
content in differentiated SH-SY5Y cells treated with the 
complex 1 inhibitor rotenone as well as PTEN-induced 
putative kinase 1 (PINK1) knock down cells [6]. Collectively 
this evidence indicates that the ability to restore PGC-1α and 
thereby mitochondrial content may provide a novel treatment 
strategy in PD and there is some evidence that this may be 
achieved by targeting the PPARγ receptor.
However, TZDs such as rosiglitazone and 
pioglitazone are known to cause adverse effects in humans 
which have resulted in their withdrawal from clinical use 
in several European countries [17] thereby creating a need 
for non-TZD activators of the receptor to be investigated 
further. One such compound may be the phytocannabinoid, 
D9-tetrahydrocannabinol (D9-THC), which has been found 
protective in 6-hydroxydopamine (6-OHDA) lesioned 
rats [18, 19] and differentiated SH-SY5Y cells treated 
with the mitochondrial complex 1 inhibitor 1-methyl-4-
phenylpyridinium iodide (MPP+) through a mechanism 
involving the PPARγ receptor, independent of cannabinoid 
receptors 1 and 2 [20].
Reduction in mitochondrial complex 1 activity is 
known to be a key feature in sporadic PD [21] and complex 
1 inhibitors are therefore widely used as a model for 
mitochondrial dysfunction in PD [22]. We used MPP+ as a 
means to model PD-associated mitochondrial dysfunction 
in differentiated SH-SY5Y cells to further investigate 
the PPARγ mediated anti-oxidant effect of D9-THC. The 
suitability of differentiated human dopaminergic SH-SY5Y 
cells in Parkinson’s disease research is still a subject of 
debate with some arguing for differentiation [23-25] and 
some against [26, 27]. However, differentiated cells are 
susceptible to MPP+ and express the required dopamine 
and noradrenalin transporters for uptake of the neurotoxin 
[24]. Furthermore, differentiation leads to a reduction in cell 
proliferation and the induction of a predominantly mature 
dopaminergic-like neurotransmitter phenotype [23, 24]. We 
therefore used differentiated SH-SY5Y cells in our study.
The primary aim of this study was to determine the 
downstream pathway through which D9-THC-mediated 
PPARγ activation leads to neuroprotection in our model 
and whether this pathway is similar to that of pioglitazone.
RESULTS
SOD1 and catalase expression are not affected 
by Δ9-THC and pioglitazone
Western blots were performed to investigate 
whether stimulation of PPARγ with Δ9-THC (10 µM) or 
pioglitazone (5 µM) led to an induction of the expression 
of its transcriptional targets SOD1 or catalase. SOD1 
(Figure 1A) and catalase (Figure 1B) expression were 
unaffected by 7 mM MPP+ treatment and remained 
unchanged by co-application of 10 µM Δ9-THC, 5 µM 
pioglitazone or co-application of T0070907.
Δ9-THC but not pioglitazone induces 
mitochondrial biogenesis
Western blots were carried out to investigate whether 
10 µM Δ9-THC and 5 µM pioglitazone led to increased 
expression of the master regulator of mitochondrial 
biogenesis PGC-1α. Figure 2A shows that protein levels 
of PGC-1α were down-regulated compared to untreated 
vehicle control upon 7 mM MPP+ treatment and restored 
by 10 µM Δ9-THC. This restoration was completely 
reversed by the addition of 10 µM T0070907, indicating 
that it was a PPARγ-mediated effect. Pioglitazone (5 µM) 
co-application also led to a significant increase in the 
PGC-1α expression compared to MPP+ alone (Figure 2A). 
Addition of T0070907 (5 µM) did not significantly block 
up-regulation of PGC-1α expression.
The transcription factor nuclear respiratory factor 
1 (NRF1) regulates the expression of nuclear encoded 
mitochondrial genes and is transcriptionally regulated 
by PGC-1α [28]. No changes were detected in NRF1 
expression with 7 mM MPP+, 10 µM Δ9-THC or 5 µM 
pioglitazone treatment (Figure 2B).
Sufficient levels of the mitochondrial transcription 
factor TFAM, as well as mtDNA replication are crucial for 
the de novo synthesis of mitochondria. TFAM expression 
was significantly reduced by 7 mM MPP+ treatment 
compared to vehicle treated cells and was fully restored 
by co-application of 10 µM Δ9-THC; this restorative 
effect was not reversed by addition of 10 µM T0070907. 
Pioglitazone (5 µM) did not restore TFAM levels (Figure 
2C). QPCR was carried out to determine the mtDNA 
content relative to nuclear DNA content. Similar to TFAM 
expression levels, mtDNA content was reduced by 7 mM 
MPP+ treatment compared to untreated vehicle control 
and only restored by co-application of 10 µM Δ9-THC in a 
PPARγ independent manner (Figure 2D).
Consequently, to determine whether Δ9-THC had 
an effect on mitochondrial biogenesis, the expression 
of COX4, a subunit of the electron transport chain, was 
measured by western blotting. Figure 2E shows that 
7 mM MPP+ treatment significantly reduced COX4 
levels compared to untreated vehicle control. Co-
application of 10 µM Δ9-THC with MPP+ completely 
restored COX4 levels, which was reversed by the 
PPARγ antagonist T0070907 (10 µM) indicating that 
the cannabinoid induces mitochondrial biogenesis in a 
PPARγ-dependent manner. 5 µM Pioglitazone had no 
significant effect on MPP+ mediated down-regulation 
of COX4 expression.
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Δ9-THC and pioglitazone act through divergent 
pathways
Given the differences in downstream effects of Δ9-
THC and pioglitazone it is possible that the protective 
effects of the two compounds may be additive when 
applied in combination. To test this hypothesis, the 
protective effects of increasing concentrations of Δ9-
THC against the toxicity of 7 mM MPP+ were assessed 
on its own and in combination with 5 µM pioglitazone 
(Figure 3A). The concentration of pioglitazone was chosen 
as it resulted in the highest protective effect in this model 
[20]. Increasing concentrations of Δ9-THC on its own led 
to dose dependent protection against MPP+. Pioglitazone 
(5 µM) alone also significantly reduced MPP+ induced cell 
death, a protective effect that was increased further by co-
application of 10 µM Δ9-THC.
This finding suggests that either the compounds 
have complementary activity on the same protective 
pathway, or they act synergistically via divergent 
downstream pathways. To clarify this further, a PPARγ 
knock down was utilised using a lenti-virus to infect SH-
SY5Y cells with PPARγ shRNA. The level of knock down 
was validated by western blotting and QPCR (Figure 3B, 
3C). PPARγ mRNA levels were reduced to 22 % relative 
to the scramble sequence and PPARγ protein levels were 
reduced in knock down samples.
Figure 3D shows that SH-SY5Y cells infected with 
scramble sequence were protected by 10 µM Δ9-THC 
against 7 mM MPP+ leading to a significant reduction in 
Figure 1: SOD1 and catalase expression. Western blot showing the effect of MPP+, Δ9-THC and pioglitazone (pio) on A. SOD1 and 
B. catalase expression. Protein data were corrected to β-actin levels which served as loading control. Each bar represents the mean ± SEM 
from 3 independent experiments (one-way ANOVA with Tukey HSD post-hoc test, no significant difference).
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Figure 2: Δ9-THC but not pioglitazone induces mitochondrial biogenesis. Western blot showing the effect of MPP+, Δ9-THC, 
pioglitazone (pio) and T0070907 (T) on A. PGC-1α expression (n = 5, one-way ANOVA with Scheffe post-hoc test), B. NRF1 expression 
(n = 5, one-way ANOVA with Tukey HSD post-hoc test) and C. TFAM expression (n = 3, one-way ANOVA with Tukey HSD post-hoc test). 
D. QPCR on genomic DNA extracts to determine the ratio between mitochondrial and genomic DNA. Cells were treated with MPP+, Δ9-THC, 
pioglitazone (pio) and T0070907 (T) (n = 3, one-way ANOVA with Tukey HSD post-hoc test). E. Western blot showing the effect of MPP+, 
Δ9-THC, pioglitazone (pio) and T0070907 (T) on COX4 expression (n = 4, one-way ANOVA with Tukey HSD post-hoc test). Protein data were 
corrected to β-actin levels which served as loading control. Each bar represents the mean ± SEM (#p<0.05, ##p<0.01, ###p<0.0001 vs. MPP+).
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cell death. This confirmed that lentiviral infection itself 
did not influence the toxicity of MPP+ or the protective 
potential of Δ9-THC. There was no significant difference in 
percentage cell death between PPARγ shRNA treated cells 
with MPP+ alone and in combination with Δ9-THC showing 
that PPARγ knock down can prevent Δ9-THC-mediated 
neuroprotection. This was further confirmed by a significant 
difference between scramble shRNA and PPARγ shRNA 
infected cells treated with Δ9-THC and MPP+. Similarly, 
cells infected with scramble shRNA could be rescued from 
cell death caused by 7 mM MPP+ with co-application of 5 
µM pioglitazone (Figure 3E). However, cells infected with 
PPARγ shRNA were neither significantly protected from 
MPP+ toxicity when co-treated with pioglitazone nor was 
there a significant difference between scramble and PPARγ 
shRNA infected cells treated with pioglitazone.
We previously demonstrated that Δ9-THC reduces 
oxidative stress in a PPARγ dependent manner [20]. We 
Figure 3: Δ9-THC and pioglitazone act through divergent pathways. A. LDH assay demonstrating the additive protective effect 
of 5 µM pioglitazone (pio) with increasing concentrations Δ9-THC against 7 mM MPP+ toxicity. B. Western Blot and C. QPCR showing 
the PPARγ protein and mRNA levels of SH-SY5Y cells infected with lentivirus containing a non-specific scramble sequence and PPARγ 
shRNA respectively. D. LDH assay showing that the PPARγ shRNA construct prevents protection afforded by 10 µM Δ9-THC against 7mM 
MPP+ but not E. 5 µM pioglitazone. F. DCFDA oxidative stress assay demonstrating that whereas knock down of PPARγ prevents 10 µM 
Δ9-THC mediated reduction in oxidative stress, PPARγ knock down does not prevent 5 µM pioglitazone-mediated reduction in oxidative 
stress. Each bar represents the mean ± SEM from 3 independent experiments (one-way ANOVA with Tukey HSD post-hoc test,*p < 0.05, 
**p < 0.001, ***p < 0.0001 vs. scramble MPP+; #p < 0.05 vs. shRNA MPP+).
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therefore investigated whether PPARγ knock down could 
prevent Δ9-THC and pioglitazone mediated anti-oxidant 
effects as assessed by DCF fluorescence. In cells infected 
with scramble sequence, 10 µM Δ9-THC treatment led to a 
significant reduction in oxidative stress compared to MPP+ 
(7 mM) treatment alone. In the shRNA knock down cells, 
oxidative stress was increased with MPP+ but there was no 
significant reduction with Δ9-THC treatment confirming 
that Δ9-THC-mediated reduction in oxidative stress is 
indeed mediated by PPARγ receptor activation. Similarly, 
Figure 3F shows that 5 µM pioglitazone significantly 
reduced reactive oxygen species (ROS) production in cells 
infected with scramble sequence. Lentiviral knock down 
of PPARγ was not able to block the reduction in ROS 
production caused by pioglitazone treatment completely.
The evidence presented here indicates that 
pioglitazone may not act exclusively through the PPARγ 
receptor. Pioglitazone has been shown to activate the 
human PPARα receptor [29]. We therefore tested whether 
the specific PPARα receptor antagonist GW6471 could 
reverse the protective effect of pioglitazone. The LDH 
assay in Figure 4A shows that GW6471 at concentrations 
of up to 0.05 µM did not increase MPP+ toxicity. 
Furthermore, 0.05 µM GW6471 reversed pioglitazone 
mediated neuroprotection against MPP+ (Figure 4B).
DISCUSSION
Δ9-THC has been found neuroprotective in PD 
and this neuroprotective effect has in the past mainly 
been attributed to the cannabinoid’s innate anti-oxidant 
structure, independent of cannabinoid receptor activity 
[18, 30, 31]. We further confirmed that the neuroprotective 
action of Δ9-THC is not cannabinoid receptor 1 (CB1 
receptor) mediated and identified the PPARγ receptor as 
a potential target through which Δ9-THC may exert its 
anti-oxidant effects [20] thereby making it unlikely that 
Δ9-THC has an effect on mitochondrial CB1 receptors 
[32] in our model, the presence of which has not yet been 
demonstrated in SH-SY5Y cells. The primary aim of the 
present study was to further assess how PPARγ receptor 
activation by Δ9-THC leads to neuroprotection and 
whether this mechanism is similar to that of the PPARγ 
agonist pioglitazone. Our data indicate that rather than 
reducing oxidative stress by PPARγ-regulated expression 
of the antioxidant enzymes SOD1 and catalase, Δ9-THC 
induces PPARγ-mediated mitochondrial biogenesis whilst 
pioglitazone, whose protective effect is most likely only 
partially driven by PPARγ, does not. Indeed our data 
suggest that Δ9-THC can add to the neuroprotective effect 
of pioglitazone.
In PD, mitochondrial function is compromised 
leading to increased production of reactive oxygen species 
thereby causing irreversible damage to proteins [33], lipids 
[34] and DNA [35] resulting in cell death [22, 36, 37]. 
Although PPARγ stimulation can play a role in modulating 
cellular redox balance by controlling the expression of 
NRF2 [38] as well as the anti-oxidant enzymes superoxide 
dismutase 1 (SOD1) and catalase [39, 40], it is not clear 
whether PPARγ-mediated protection against oxidative 
stress in the MPP+ model of PD involves SOD1 and 
catalase as one group demonstrated increased activity and 
Figure 4: Inhibition of PPARα blocks the protective effect of pioglitazone. LDH assay showing the effect of increasing 
concentrations of PPARα antagonist GW6471 on A. the toxicity of 7 mM MPP+ and B. the protective effect of pioglitazone. Each bar 
represents the mean ± SEM of quadruplicate measurements from 3 independent experiments (one-way ANOVA with Tukey HSD post-hoc 
test; *p < 0.05, **p < 0.001 vs. MPP+).
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expression of the enzymes [2] in response to rosiglitazone 
treatment whilst another found that SOD1 activity and 
expression remained unchanged [41]. We found SOD1 
and catalase expression to be unchanged by MPP+, Δ9-
THC or pioglitazone treatment, suggesting that these 
enzymes were not involved in Δ9-THC or pioglitazone 
mediated neuroprotection. The PPARγ receptor is able 
to regulate the expression of a vast variety of target 
genes. It is now increasingly recognised that the extent 
of expression of these genes can vary depending on the 
agonist used as they may alter intracellular factors such as 
the availability of specific co-activators [42], interaction 
with other nuclear receptors [43] as well as receptor 
phosphorylation, ubiquitination and sumoylation [44, 
45]. This might explain why, despite being PPARγ target 
genes, neither Δ9-THC nor pioglitazone had any effect 
on catalase or SOD1 expression. Complex 1 inhibition, 
which has been associated with sporadic PD [21, 46, 
47], leads to reduced expression of proteins necessary 
for the de novo synthesis of mitochondria. Specifically, 
PGC-1α and TFAM expression has been shown to be 
decreased in MPP+ treated SH-SY5Y cells resulting in 
reduced mitochondrial content, closely mirroring our 
findings [48, 49]. Reduced mitochondrial content seems 
to be a common phenomenon in patients with sporadic PD 
[13] as well as familial models of PD including neurons 
overexpressing the A53T mutation of α-synuclein [15] 
and neurons expressing mutant leucine rich repeat kinase 
2 (LRRK2) [50]. Furthermore, transcriptional activity of 
PGC-1α is regulated by parkin and therefore mutations 
that impair the functionality of parkin also impact 
mitochondrial biogenesis [16, 51, 52]. Hence, treatments 
that induce mitochondrial biogenesis may be of particular 
benefit in PD.
PGC-1α is a target of PPARγ activation with the 
potential ability to reduce oxidative stress [12]. As well as 
co-activating the PPARγ receptor and thereby enhancing 
the transcriptional activity of PPARγ, PGC-1α is known 
as the master-regulator of mitochondrial biogenesis as it 
orchestrates the expression of transcription factors TFAM 
and NRF1 which are responsible for transcription of 
mitochondrial as well as nuclear encoded mitochondrial 
genes respectively [15, 28]. We therefore hypothesised 
that, by activating PPARγ, pioglitazone and Δ9-THC 
might induce the expression of PGC-1α which may in 
turn stimulate the transcription of components essential 
for mitochondrial biogenesis. Restoration of PGC-
1α expression can reverse reduction in mitochondrial 
content which has been found protective in models 
using complex 1 inhibitors such as 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) and rotenone [13, 14], 
A53T mutations of α-synuclein [13, 15] and α-synuclein 
oligomerisation [53].
Both Δ9-THC and pioglitazone treatment led to 
restoration of PGC-1α levels in our MPP+ treated cells. 
However, only Δ9-THC was able to simultaneously restore 
TFAM and mtDNA levels leading to increased COX4 
expression which we used as a marker for mitochondrial 
biogenesis. There is evidence that restoration of TFAM can 
reverse mitochondrial deficits and increase mitochondrial 
density in MPP+ treated SH-SY5Y cells [48, 49]. TFAM 
may play a direct role in the stabilisation and maintenance 
of mtDNA as TFAM knock down leads to accumulation 
of mtDNA mutations [54] whilst its overexpression 
increases mtDNA content [55] as well as expression of 
mitochondria encoded electron transport chain subunits 
[55, 56]. We suggest that whilst reduced TFAM expression 
can become rate limiting to mitochondrial biogenesis, 
it requires the presence of PGC-1α to co-ordinate the 
production of new mitochondria as it co-activates NRF1 
mediated transcription of nuclear encoded mitochondrial 
subunits [28]. Therefore, pioglitazone was unable to 
induce mitochondrial biogenesis as, despite increasing 
PGC-1α expression, it lacked the ability to restore TFAM 
levels. It is not clear whether increasing mitochondrial 
density and mtDNA levels would be protective long term 
as newly produced mitochondria might still be vulnerable 
to oxidative damage. Therefore, future experiments may 
include investigating rates of DNA oxidation in response 
to Δ9-THC treatment.
Whilst we have identified a potential mechanism 
through which Δ9-THC can be anti-oxidant, namely by 
increasing mitochondrial biogenesis, the mechanism 
which mediates the anti-oxidant effect of pioglitazone 
remains unclear. Lipophilicity is thought to be a key 
determinant of the biological activity of drugs as it plays 
a role in their bioavailability. Both pioglitazone and Δ9-
THC are lipophilic compounds with a log P value of 4 
and 6.97 respectively [57, 58]. Whilst in theory higher 
lipophilicity may increase the ability of a compound to 
cross membranes and therefore reach an internal target 
receptor, this is also dependent on other factors such 
as charge and size of the compound. It is, however, 
unlikely that Δ9-THC is more potent at activating PPARγ 
solely because of its higher lipophilicity as some studies 
looking at the relationship between lipophilicity and 
PPARγ activation within the TZD family found no 
correlation between lipophilicity and PPARγ activity 
[59].
Interestingly, pioglitazone has been shown to 
bind and activate PPARα in the micromolar range [29] 
which can also induce PGC-1α expression and reduce 
oxidative stress [60]. This might explain the PPARγ 
independent increase in PGC-1α expression in response 
to pioglitazone treatment. Our preliminary results indicate 
that pioglitazone could, at least in part, act through 
activation of the PPARα receptor as the protective effect 
of pioglitazone can be reversed with the specific inhibitor 
GW6471. Furthermore, PPARα activation by fenofibrate 
and palmitoylethanolamide (PEA) has been found 
neuroprotective against 6-OHDA and MPTP mediated 
toxicity respectively [61-63]. Alternatively, like other 
thiazolidinediones, pioglitazone could have other receptor 
independent anti-oxidant effects [38, 41, 64].
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Our results show that whilst both D9-THC and 
pioglitazone reduced oxidative stress and restored PGC-
1α levels, only D9-THC had the ability to induce TFAM 
expression and restore mitochondrial DNA (mtDNA) 
levels leading to increased cytochrome c oxidase subunit 
4 (COX4) expression which had been almost completely 
diminished by MPP+. Furthermore, lentiviral knock down 
experiments indicated that only the D9-THC mediated 
protective effect was exclusively mediated by PPARγ. 
Co-application experiments with pioglitazone show that 
Δ9-THC adds to the neuroprotective effect of pioglitazone 
thereby suggesting that the two compounds act through 
divergent pathways and provide the first evidence that 
the cannabinoid could be an alternative protective 
strategy to TZDs by restoring mitochondrial content in a 
PPARγ-dependent manner. Although not assessed in the 
current study, it is possible that Δ9-THC would also have 
neuroprotective effects additional to those postulated for 
monoamine oxidase inhibitors (MAOIs), widely used 
in clinical practice, whose mode of action is thought to 
be anti-apoptotic, largely independent of their MAO 
effects [65]. This raises the possibility of these drugs 
being utilised in combination to maximise any clinical 
neuroprotective benefit and merits further investigation.
In recent years, PPARγ agonists have been 
considered as promising therapeutic agents for the 
treatment of PD [66]. However, the clinical potential 
of classical TZD-based PPAR agonists is limited with 
rosiglitazone having been withdrawn from clinical use in 
Europe due to its cardiovascular toxicity and pioglitazone 
being banned in Germany and France due to an associated 
risk for the development of bladder cancer [17]. By 
contrast, Δ9-THC is generally well tolerated by PD 
patients [67] and may therefore represent an alternative 
worthy of consideration. Furthermore, the ability of Δ9-
THC to induce mitochondrial biogenesis is interesting as 
decreased mitochondrial content has been associated with 
familial as well as sporadic cases of PD.
MATERIALS AND METHODS
Chemicals were purchased from Sigma-Aldrich 
Chemicals (Dorset, UK) unless stated otherwise.
Culture of neuroblastoma cells
Human neuroblastoma cells (SH-SY5Y) were 
obtained from the European collection of cell cultures 
(ECACC) and grown in Dulbecco’s modified Eagle’s 
medium (Invitrogen, Paisley, UK) containing 10% (v/v) 
foetal bovine serum (FBS) (PAA, Yeovil, UK), glutamine, 
4.5 g/l glucose, 1 ml uridine (25 mg/ml), 5 ml pyruvate, 
25 units/ml penicillin and 25 µg/ml streptomycin, and 
incubated at 37ºC in a humidified atmosphere of 5% CO2 
and 95% air. For experiments, cells were seeded in 6-well 
dishes (200,000 cells/well) or 96-well plates (10,000 
cells/well). After allowing the cells to attach for 24 hours, 
they were treated with 10 µM retinoic acid for 5 days 
to promote differentiation to a neuronal phenotype after 
which the cells were 90% confluent. Medium was changed 
every 48 hrs.
Cell treatments
All treatments were made up in retinoic acid 
supplemented medium (10 µM). After differentiation, cells 
were treated with 7 mM MPP+ as well as 10 µM D9-THC 
or 5 µM pioglitazone for 48 hours. These concentrations 
were previously found to be protective in our cell culture 
model [20]. The minimum dose of the PPARγ inhibitor 
T0070907 required to completely reverse the protective 
effect of D9-THC and pioglitazone was used, 10 µM and 5 
µM respectively (Carroll et al., 2012).
Lentiviral knock down of PPARγ
Cells were seeded into 6 well plates and grown to 
90% confluency. The cationic polymer polybrene was 
added to growth medium at a final concentration of 8 µg/
ml. Pre-packaged high titre lentivirus containing PPARG 
shRNA 239215 (Open Biosystems, Fisher, Loughborough, 
UK) was defrosted at 37 °C and 1 µl was added per well 
(multiplicity of infection = 31.8). Cells were incubated 
with the virus for 24 hours after which medium was 
replaced with selection medium containing 4 µg/ml 
puromycin. After 48 hours the concentration of puromycin 
was lowered to 2 µg/ml to ensure normal growth of 
cells which were kept at this concentration throughout 
all experiments. A lentivirus containing a non-specific 
scramble sequence was used as a control.
LDH-release assay
To assess the cytotoxicity of the toxins under our 
experimental conditions, lactate dehydrogenase (LDH) 
release of cells grown and treated in 96-well plates was 
measured. Cell culture medium (50 µl) was used to 
analyse the LDH activity by measuring the oxidation 
of NADH at 450 nm as described in the manufacturer’s 
protocol (Promega, Southampton, UK). The remaining 
cells were lysed at -80°C and LDH activity similarly 
measured to allow the percentage of cell death relative to 
the total number of cells to be calculated.
Measurement of reactive oxygen species
SH-SY5Y cells were seeded into 96 well plates and 
treated for 48 hours as described above. The medium was 
removed and cells were incubated in serum free medium 
containing 10 μM 2′,7′-dichlorofluorescein diacetate 
(DCFDA) for 30 minutes. Cells were then washed 3 times 
with PBS after which the fluorescence was measured at 
Ex: 485 nm and Em: 535 nm. Surviving cells were lysed 
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at -80 °C and an LDH assay carried out. DCF fluorescence 
readings were then normalised to LDH absorbance to 
control for variations in cell number. Experiments were 
carried out 3 times in quadruplicate.
Protein extraction and western blot analysis
Surviving cells were lysed for protein extraction 
48 hours following exposure to treatments. Cells 
were washed with ice-cold PBS and protein extracted 
with NET-Triton buffer (150 mM NaCl, 5 mM 
EDTA (ethylenediaminetetraacetic acid), 10 mM Tris 
(tris(hydroxymethyl)aminomethane), pH 7.4, 1% Triton 
X-100) supplemented with complete protease inhibitor 
cocktail (Roche Diagnostics, Lewes, UK) according to the 
manufacturer’s instructions.
The proteins were resolved by SDS/PAGE (10% 
gels) and blotted onto polyvinylidene fluoride (PVDF) 
membranes. Membranes were washed with tris-buffered 
saline (140 mM NaCl, 50 mM tris/HCl, pH 7.2) containing 
0.1% Tween 20, 5% skimmed milk and 2% bovine serum 
albumin to block non-specific protein binding.
Membranes were incubated with primary antibody 
against PPARγ receptor (1:1000, 2435S New England 
Biolabs, Hitchin, UK) (57 kDa), SOD1 (1:1000, ab16831, 
Abcam, Cambridge, UK) (17 kDa), catalase (1:1000, 
ab16731, Abcam, Cambridge, UK) (60 kDa), PGC-1α 
(1:500, ab77210, Abcam, Cambridge, UK) (91 kDa), 
TFAM (1:1000, 8076, New England Biolabs, Hitchin, 
UK) (24 kDa), NRF1 (1:1000, ab55744, Abcam, 
Cambridge, UK) (54 kDa), COX4 (1:1000, ab33985, 
Abcam, Cambridge, UK) (15 kDa), in tris-buffered saline 
(140 mM NaCl, 50 mM tris/HCl, pH 7.2) containing 0.1% 
Tween 20 (TBST), 5% skimmed milk and 2% bovine 
serum albumin overnight at 4ºC. PGC-1α antibody (1:500, 
ab77210, Abcam, Cambridge, UK) was incubated in TBST 
containing 5% bovine serum albumin overnight at 4 ºC. 
Subsequently membranes were washed 3 times in TBST 
and incubated with horseradish-peroxidase-conjugated 
secondary antibody (Bio-Rad, Hemel Hempstead, UK) 
for 1 h at room temperature. The protein bands were 
detected using ECL2 (Thermo Scientific, Rockford, US). 
Membranes were probed with β-actin (1:10000, ab8227, 
Abcam, Cambridge, UK) to control for loading. Samples 
were analysed from at least three separate experiments.
Measuring mitochondrial DNA content
Cells were grown and treated in 6 well plates. Total 
DNA was extracted using the QIAamp DNA Mini Kit 
(QIAGEN, Crawley, UK) following the manufacturer’s 
instructions for cultured cells. Changes in mtDNA content 
were then determined by QPCR. Specific primer pairs were 
designed to recognise a sequence from the mitochondrial 
genome (FW: CCCTATGTCGCAGTATCTGTCTTT; Rev: 
AGATGTGTTTAAGTGCTGTGGC) and the nuclear 
gene Pou5f1 (FW: CCTTCGCAAGCCCTCATTTC, 
Rev: TAGCCAGGTCCGAGGATCAA). QPCR was 
performed in a 50 µl reaction containing 25 µl 2x SYBR® 
GreenER™ mastermix, 1 µl/primer and 2 µl DNA. In a 
Biorad ICycler samples were heated to 50 ºC for 2 minutes 
followed by 95 ºC for 10 minutes. Samples were then 
cycled through 40 cylces of 95 ºC for 15 seconds and 63 
ºC for 1 minute. A fluorescent signal was measured at Em: 
520 nm when excited at Ex: 497 nm.
Each sample was run in triplicate. The ΔΔCT method 
was used to calculate fold changes in mtDNA content.
Data analysis and statistical procedures
All numerical data are presented as mean ± 1 
standard error of the mean. Each experiment was carried 
out at least 3 times. Statistical significance was determined 
with SPSS using one way analysis of variance (ANOVA) 
with a significance threshold of 95%, unless stated 
otherwise. To compare levels of significance between 
groups, an appropriate post-hoc test was chosen according 
to the assumptions of the test.
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